Patient Disease:
Canine Mast Cell Tumor
Study Name:
Combination Therapy with Gilvetmab and Toceranib in Dogs with Mast Cell Tumors
Purpose of the study:
- To characterize the antitumor effects and adverse effect profile of combined treatment with gilvetmab and toceranib in dogs with measurable mast cell tumor (MCT)
Primary Eligibility Criteria:
- Confirmed diagnosis of MCT with a tumor at least 1 cm in diameter
- Weight at least 10 kg (22 lb)
- Adequate organ function
- 72-hour washout from corticosteroids, 2 weeks from chemotherapy, and 6 weeks from radiation
- No prior treatment with drug similar to toceranib or gilvetmab
- Pets must come to CSU for all visits related to the clinical trial
Study Protocol:
- All dogs must be on cetirizine and omeprazole for at least 3 days prior to starting treatment
- Gilvetmab will be given as an IV infusion every 2 weeks for up to 10 treatments, and toceranib will be given orally every other day
- Visits required every 2 weeks until week 20 then every 6 weeks for exam, diagnostics, and treatment
- Dogs with a complete response will discontinue toceranib treatment after the week 20 visit
Owner Responsibilities:
- Costs of diagnostics to determine eligibility for the trial, cetirizine and omeprazole, administration fee for gilvetmab, and treatment of side effects related to toceranib
- If your dog is found to have spread of the tumor to the abdomen or chest at screening, you will be responsible for the cost of rechecking these diagnostics every 6 weeks during the study
- Administer oral medications to your dog
- Make and keep all appointments as required by the clinical trial protocol
Financial Incentives:
- Once enrolled, the study will cover the costs related to recheck exams, blood/urine testing, and the costs of toceranib and gilvetmab drug
- Up to $500 is available to cover costs of treatment of side effects related to gilvetmab treatment
If you have further questions about any of our clinical trials, please submit an online consult form. Your consult will then be directed to our trials team. Requests are typically returned within 5 business days.